3-Cyano-6-(2 methoxyphenyl)-2(1H)-pyridinone | 128173-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Cyano-6-(2 methoxyphenyl)-2(1H)-pyridinone
• 英文别名: 3-Cyano-6-(2-methoxyphenyl)-2(1H)-pyridinone；2-Hydroxy-6-(2-methoxy-phenyl)-nicotinonitrile；6-(2-methoxyphenyl)-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 128173-60-4
• 化学式: C₁₃H₁₀N₂O₂
• mdl: MFCD16435453
• 分子量: 226.235
• InChiKey: BUSZQHDWBAPALC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Cyano-6-(2 methoxyphenyl)-2(1H)-pyridinone 在 三溴化硼 、 一水合肼 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 28.0h， 生成
  参考文献：
  名称：

  6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)

  摘要：

  A novel series of 6-aryl-pyrazolo[3,4-b]pyridines has been identified that are potent inhibitors of glycogen synthase kinase-3 (GSK-3).(C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00645-0
• 作为产物：
  描述：

  2'-甲氧基苯乙酮 在 三乙烯二胺 作用下， 以 乙醇 为溶剂， 生成 3-Cyano-6-(2 methoxyphenyl)-2(1H)-pyridinone
  参考文献：
  名称：

  Discovery and structure–activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors

  摘要：

  Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[ 2,3-b] pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 mu M, SI > 30.3, 12b, EC50 = 3.5 mu M, SI > 28.6, 10l, EC50 = 3.9 mu M, SI > 25.6, 12o, EC50 = 4.5 mu M, SI > 22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.075

文献信息

• Method of treating a patient having precancerous lesions with phenyl
  申请人：Cell Pathways, Inc.

  公开号：US06046216A1

  公开（公告）日：2000-04-04

  Derivatives of phenyl pyridinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.

  苯基吡啶酮的衍生物对于治疗患有癌前病变的患者非常有用。这些化合物还可用于抑制肿瘤细胞的生长。
• Chemical compounds
  申请人：Smith Kline & French Laboratories Ltd.

  公开号：US05254571A1

  公开（公告）日：1993-10-19

  This invention relates to phenylpyridone derivatives which have bronchodilator and anti-allergic activities. A compound of the invention is 6-(2-propoxyphenyl)-1,2-dihydro-2-oxopyridine-3-carboxamide.

  本发明涉及具有支气管扩张剂和抗过敏活性的苯基吡啶酮衍生物。该发明的化合物是6-（2-丙氧基苯基）-1,2-二氢-2-氧代吡啶-3-羧酰胺。
• Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
  申请人：Cell Pathways, Inc.

  公开号：US06479520B1

  公开（公告）日：2002-11-12

  Derivatives of phenyl pyridinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.

  苯基吡啶酮的衍生物对于治疗患有癌前病变的患者非常有用。这些化合物还可以用于抑制肿瘤细胞的生长。
• Phenylpyridone derivatives,processes for their preparation and pharmaceutical compositions containing them.
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0347027A2

  公开（公告）日：1989-12-20

  Compounds of the formula (1): and pharmaceutically acceptable salts are described, wherein X is O or S; R¹ is C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₅cycloalkylC₁₋₄alkyl, or C₁₋₄alkyl substituted by 1 to 6 fluoro groups; R² is hydrogen, -CN, -CONR⁵R⁶, -CO₂R⁷, 5-tetrazolyl, -NO₂, -NH₂ or -NHCOR⁸ wherein R⁵, R⁶, R⁷ and R⁸ are independently hydrogen or C₁₋₄alkyl; R³ is hydrogen or C₁₋₄alkyl; and R⁴ is hydrogen or C₁₋₄alkyl; with the proviso that R¹ is not methyl when R² is -CO₂H, -CO₂CH₂CH₃ or -CN, X is 0, R³ is hydrogen and R⁴ is hydrogen or methyl. These compounds have bronchodilator, anti-allergic, vasodilator and anti-inflammatory activities. Pharmaceutical compositions are described as are methods of use. Processes for the preparation of the compounds of the formula (1) are described.

  描述了式(1)化合物 和药学上可接受的盐，其中 X 是 O 或 S；R¹ 是 C₁₋₆烷基、C₂₋₆烯基、C₃₋₅环烷基或被 1 至 6 个氟基团取代的 C₁₋₄ 烷基；R² 是氢、-CN、-CONR⁵R⁶、-CO₂R⁷、5-四唑基、-NO₂、-NH₂ 或 -NHCOR⁸，其中 R⁵、R⁶、R⁷ 和 R⁸ 独立地是氢或 C₁₋₄；R³是氢或C₁₋₄alkyl；R⁴是氢或C₁₋₄alkyl；但R¹不是甲基，当R²是-CO₂H、-CO₂CH₂CH₃或-CN时，X是0，R³是氢，R⁴是氢或甲基。 这些化合物具有支气管扩张、抗过敏、血管扩张和抗炎活性。本文介绍了药物组合物以及使用方法。描述了式 (1) 化合物的制备工艺。
• US5254571A
  申请人：——

  公开号：US5254571A

  公开（公告）日：1993-10-19